PHOENIX — Obese individuals lost 14% of their weight on average at the highest dose in a blinded, randomized, placebo-controlled trial of a novel weight loss drug combining slow-release formulations of the anticonvulsant zonisamide and the antidepressant bupropion.
PREVIEW